Bluejay Diagnostics (BJDX) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 05, 2023
Document Information Line Items
Entity Registrant Name	Bluejay Diagnostics, Inc.
Trading Symbol	BJDX
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,459,057
Amendment Flag	false
Entity Central Index Key	0001704287
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41031
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3552922
Entity Address, Address Line One	360 Massachusetts Avenue,
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
City Area Code	(844)
Local Phone Number	327-7078
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,781,911	$ 10,114,990
Prepaid expenses and other current assets	2,120,012	1,673,480
Total current assets	8,901,923	11,788,470
Property and equipment, net	1,519,722	1,232,070
Operating lease right-of-use assets	433,361	465,514
Other non-current assets	33,443	35,211
Total assets	10,888,449	13,521,265
Current liabilities:
Accounts payable	388,045	635,818
Operating lease liability, current	168,709	168,706
Accrued expenses and other current liabilities	863,397	835,730
Total current liabilities	1,420,151	1,640,254
Operating lease liability, non-current	289,910	323,915
Other non-current liabilities	14,970	15,823
Total liabilities	1,725,031	1,979,992
Commitments and Contingencies (See Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 20,459,057 and 20,215,288 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	2,046	2,022
Additional paid-in capital	28,698,317	28,536,353
Accumulated deficit	(19,536,945)	(16,997,102)
Total stockholders’ equity	9,163,418	11,541,273
Total liabilities and stockholders’ equity	$ 10,888,449	$ 13,521,265

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	20,459,057	20,215,288
Common stock, shares outstanding	20,459,057	20,215,288

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 1,354,549	$ 694,757
General and administrative	1,176,977	1,319,819
Sales and marketing	148,046	53,685
Total operating expenses	2,679,572	2,068,261
Operating loss	(2,679,572)	(2,068,261)
Other income:
Other income, net	139,729	54,858
Total other income	(139,729)	(54,858)
Net loss	$ (2,539,843)	$ (2,013,403)
Net loss per share - Basic and diluted (in Dollars per share)	$ (0.12)	$ (0.1)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	20,375,092	20,142,300

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net loss per share - Diluted	$ (0.12)	$ (0.10)
Diluted	20,375,092	20,142,300

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 2,011	$ 28,074,484	$ (7,694,786)	$ 20,381,709
Balance (in Shares) at Dec. 31, 2021	20,112,244
Impact of adoption of ASC 842			(5,368)	(5,368)
Impact of adoption of ASC 842 (in Shares)
Stock-based compensation expense		126,086		126,086
Stock-based compensation expense (in Shares)
Exercise of common stock Series B Warrants	$ 4	(4)
Exercise of common stock Series B Warrants (in Shares)	39,000
Net loss			(2,013,403)	(2,013,403)
Net loss
Balance at Mar. 31, 2022	$ 2,015	28,200,566	(9,713,557)	18,489,024
Balance (in Shares) at Mar. 31, 2022	20,151,244
Balance at Dec. 31, 2022	$ 2,022	28,536,353	(16,997,102)	11,541,273
Balance (in Shares) at Dec. 31, 2022	20,215,288
Stock-based compensation expense		54,730		54,730
Stock-based compensation expense (in Shares)
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld	$ 24	107,234		107,234
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld (in Shares)	243,769
Net loss			(2,539,843)	(2,539,843)
Net loss
Balance at Mar. 31, 2023	$ 2,046	$ 28,698,317	$ (19,536,945)	$ 9,163,418
Balance (in Shares) at Mar. 31, 2023	20,459,057

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (2,539,843)	$ (2,013,403)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	120,017	39,971
Stock-based compensation expense	219,589	126,086
Amortization of right-of-use asset	40,328	28,238
Changes in operating assets and liabilities:
Inventory		(893,174)
Prepaid expenses and other current assets	(446,532)	309,958
Other non-current assets	1,768	788
Accounts payable	(314,773)	421,058
Due to related party		(2,000)
Accrued expenses and other current liabilities	(14,161)	105,223
Net cash used in operating activities	(2,933,607)	(1,877,255)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(340,669)	(46,346)
Net cash used in investing activities	(340,669)	(46,346)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of tax withholding obligations on restricted stock units	(57,601)
Payment of finance lease	(1,202)
Net cash used in financing activities	(58,803)
Decrease in cash and cash equivalents	(3,333,079)	(1,923,601)
Cash and cash equivalents, beginning of period	10,114,990	19,047,778
Cash and cash equivalents, end of period	6,781,911	17,124,177
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Liabilities incurred for the purchase of property and equipment	$ 67,000

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces laboratory-quality results in less than 20 minutes in intensive care units and emergency rooms, where rapid and reliable results are required. Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker with rapid results. In the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States. Bluejay’s operations to date have been funded primarily through the proceeds of the Company’s initial public offering (the “IPO”) in November 2021 (the “IPO Date”). On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis. Risks and Uncertainties The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies and dependence on key personnel. The Company is also impacted by inflationary pressures and global supply chain disruptions currently impacting many companies. On October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company intends to take all reasonable measures available to achieve compliance and allow for continued listing on the Nasdaq Capital Market. However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria. Going Concern The Consolidated Financial Statements for the years ended March 31, 2023 and 2022 were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has incurred net losses since its inception, and has negative cash flows from operations and will need additional funding to complete planned development efforts. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company had cash and cash equivalents of $6.8 million at March 31, 2023. It continues to develop the Symphony device and its first test for the measurement of IL-6. It remains committed to obtaining FDA clearance and is expanding clinical trials to obtain additional data to support its FDA submission, while also continuing to build its manufacturing operations with its contract manufacturing organizations. Current cash resources and expected operating expenses are considered in determining its liquidity requirement; as well as $1.4 million of current liabilities on its balance sheet at March 31, 2023 and capital commitments of approximately $2.5 million as of March 31, 2023 (see Notes 8 and 9). The Company estimates cash resources will be sufficient to fund its operations into the fourth quarter of 2023. The Company will need additional capital to fund its planned operations for the next 12 months. The Company may seek to raise such additional capital through public or private equity offerings, grant financing and support from governmental agencies, convertible debt, collaborations, strategic alliances and distribution arrangements. Additional funds may not be available when it needs them on terms that are acceptable to them, or at all. If adequate funds are not available, it may be required to delay or reduce the scope of its research or development programs, its commercialization efforts or its manufacturing commitments and capacity. In addition, if it raises additional funds through collaborations, strategic alliances or distribution arrangements with third parties, it may have to relinquish valuable rights to its technologies or future revenue streams. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2023, its results of operations and cash flows for the three months ended March 31, 2023 and 2022, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other interim period within this fiscal year.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2 . During the three months ended March 31, 2023, there were no changes to the significant accounting policies as described in the 2022 Audited Financial Statements. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements. Stock-based compensation Share-based compensation expense for all share-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Share-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of share-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense. Research and development expenses Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials. The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. Segment Reporting Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of March 31, 2023 and December 31, 2022, all of the Company’s assets were located in the United States. Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares): March 31, 2023 2022 Options to purchase common stock 739,835 806,065 Restricted stock units 197,500 - Warrants for common stock 811,882 811,882 Class A warrants for common stock 2,484,000 2,484,000 Class B warrants for common stock 75,400 76,500 Recently Adopted Accounting Standards In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 805”) Revenue from Contracts with Customers (Topic 606) (“

License and Supply Agreement wi

License and Supply Agreement with Toray Industries	3 Months Ended
	Mar. 31, 2023
License and Supply Agreement with Toray Industries [Abstract]
LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES	3. LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES On October 6, 2020, the Company entered into a License and Supply Agreement (“License Agreement”) with Toray Industries, Inc. (“Toray”). Under the License Agreement, the Company received the exclusive license (outside of Japan) to make and distribute protein detection cartridges that have a function of automatic stepwise feeding of reagent (the “Cartridges”). In addition, following the first sale of the Cartridges after regulatory approval, the Company will make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or five years after the first sale. Following the first sale after obtaining regulatory approval, the Company will make minimum annual royalty payments of $60,000 for the first year and $100,000 for each year thereafter, which shall be creditable against any royalties owed to Toray in such calendar year. There were no sales of or revenues from the Cartridges during the three-month periods ended March 31, 2023 and 2022. At March 31, 2023 and December 31, 2022, there were no amounts accrued related to the License Agreement.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2023
Warrants [Abstract]
WARRANTS	4. WARRANTS The following table summarizes information with regard to warrants outstanding at March 31, 2023: Shares Exercisable for Weighted Average Exercise Price Weighted Average Remaining Life (in Years) Common Stock Warrants 811,882 Common Stock $ 3.24 2.8 Class A Warrants 2,484,000 Common Stock $ 7.00 3.6 Class B Warrants 75,400 Common Stock $ 10.00 1 3.6 1 Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below. No warrants were issued during the three months ended March 31, 2023 and 2022. Class A Warrants and Class B Warrants In conjunction with the Company’s IPO in November 2021 the Company issued 2,160,000 Class A Warrants and 2,160,000 Class B Warrants. Additionally, the underwriter of the IPO exercised their overallotment option, solely with respect to the Class A Warrants and Class B Warrants, shortly after the IPO Date resulting in an additional issuance of 324,000 Class A Warrants and 324,000 Class B Warrants. From the net IPO proceeds, $5,164,751 and $7,323,161, respectively, were apportioned to the Class A Warrants and Class B Warrants. Class A Warrants entitle the holder to purchase one share of common stock at an exercise price of $7.00 per share. As of March 31, 2023 and 2022 all Class A Warrants were outstanding. Class B Warrants entitle the holder to purchase one share of common stock at an exercise price of $10.00 per share. Holders of Class B Warrants may also exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement). During the three months ended March 31, 2023, no Class B Warrants were exercised, while during the three months ended March 31, 2022, 39,000 Class B Warrants were exercised, all on a cashless basis. As of March 31, 2023 and 2022, respectively,75,400 and 76,500 Class B Warrants were outstanding.

Stock Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2023
Stock Compensation [Abstract]
STOCK COMPENSATION	5. STOCK COMPENSATION Stock Incentive Plans In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Board of Directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is 629,440. At March 31, 2023, there were 262,269 shares available for grant under the 2018 Plan. On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Plan”). A total of 1,960,000 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. At March 31, 2023, there were 807,541 shares available for grant under the 2021 Plan. Stock Award Activity The following table summarizes the status of the Company’s non-vested restricted stock awards for the three months ended March 31, 2023: Non-vested Number of Weighted Outstanding at December 31, 2022 60,000 $ 1.29 Granted 512,180 0.44 Vested (374,680 ) 0.44 Forfeited - - Outstanding at March 31, 2023 197,500 $ 0.70 In February 2023, the Company issued 374,680 fully vested restricted stock units to certain employees in lieu of cash to satisfy their 2022 bonuses. The number of restricted stock unit awards issued were determined based on the approved bonus amount divided by the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as stock compensation expense on the date of grant with a reversal of the related accrued bonus recorded in 2022. The following is a summary of stock option activity for the nine months ended March 31, 2023: Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 719,835 $ 1.96 6.5 $ 20,578 Granted 20,000 0.53 Exercised - - - - Cancelled and forfeited - - - - Outstanding at March 31, 2023 739,835 $ 1.92 7.7 $ 23,316 Exercisable at March 31, 2023 564,440 $ 1.86 7.4 $ 23,316 The weighted average grant date fair value of options granted during the three months ended March 31, 2023 and 2022 was $0.44 per share and $1.48 per share, respectively. The Company calculated the grant-date fair value of stock option awards granted during the three months ended March 31, 2023 and 2022 using the Black-Scholes model with the following assumptions: Three Months Ended 2023 2022 Risk-free interest rate 3.63% 1.58% - 2.40% Expected dividend yield 0.00% 0.00% Volatility factor 108.78% 102.03% Expected life of option (in years) 6.00 5.37 – 6.00 Stock-Based Compensation Expense For the three months ended March 31,2023 and 2022, the Company recorded stock-based compensation expense as follows: Three Months Ended 2023 2022 Research and development $ 44,845 $ 17,311 General and administrative 159,584 108,305 Sales and marketing 15,160 470 Total stock-based compensation $ 219,589 $ 126,086 At March 31, 2023, there was approximately $114,985 of unrecognized compensation expense related to non-vested stock option awards that are expected to be recognized over a weighted-average period of 1.8 years. At March 31, 2023, there was approximately $89,451 of unrecognized compensation expense related to non-vested restricted stock awards that are expected to be recognized over a weighted-average period of 1.1 years.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS NanoHybrids, LLC In December 2021, the Company entered into an agreement with NanoHybrids, LLC (“NanoHybrids”) to utilize the Company’s research and development staff and laboratory facility when available to perform work for NanoHybrids. Any hours worked by Company employees for NanoHybrids is billed to NanoHybrids at a bill rate of the respective employee’s fully burdened personnel cost plus 10%. Additionally, the Company may purchase certain lab supplies for NanoHybrids and rebill these costs to NanoHybrids. NanoHybrids is wholly owned by the Company’s Chief Technology Officer. The table below summarizes the amounts earned and due from NanoHybrids as of and for the three month periods’ ended March 31, 2023 and 2022, and balances due as of March 31, 2023 and December 31, 2022: Three Months Ended 2023 2022 Income from NanoHybrids included in Other Income $ 95,798 $ 40,886 Cash receipts from NanoHybrids $ 19,731 $ 22,539 As of March 31, December 31, Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets $ 95,798 $ 19,731

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT Property and equipment consisted of the following at March 31, 2023 and December 31, 2022: Depreciable March 31, December 31, Construction-in-process $ 768,850 $ 375,466 Furniture, fixtures, and equipment 3-5 years 143,649 136,942 Software 3-5 years 4,457 4,457 Lab equipment 3-5 years 1,275,958 1,268,380 Leasehold improvements Shorter of useful life of life of lease 43,231 43,231 2,236,145 1,828,476 Less: accumulated depreciation (716,423 ) (596,406 ) Property and equipment, net $ 1,519,722 $ 1,232,070 The Company reviews long-lived assets for impairment when events, expectations, or changes in circumstances indicate that the asset’s carrying value may not be recoverable. As a result of this review in the first quarter of 2023, no impairment was recorded, however, the Company revised the useful life of certain lab equipment in the first quarter of 2023 due to a change in expectations of the time the equipment will be used which resulted in approximately $45,000 of additional depreciation recorded in the three months ended March 31, 2023.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
LEASES	8. LEASES The Company primarily enters into lease arrangements for office and laboratory space. A summary of supplemental lease information is as follows: Three Months Ended March 31, March 31, Weighted average remaining lease term – operating leases (in years) 3.5 4.3 Weighted average remaining lease term – finance leases (in years) 4.8 - Weighted average discount rate 7.0 % 7.0 % Operating cash flows from operating leases $ 43,564 $ 29,248 Operating cash flows from finance leases $ 1,202 - A summary of the Company’s lease assets and liabilities are as follows: March 31, December 31, Operating lease right-of-use asset $ 433,361 $ 465,514 Finance lease asset – property & equipment, net 21,067 21,067 Total lease assets 454,428 486,581 Current portion of operating lease liability included in accrued expenses 168,709 168,706 Current portion of finance lease liability included in accrued expenses 4,807 4,807 Non-current operating lease liabilities 289,910 323,915 Non-current finance lease liabilities included in other non-current liabilities 14,970 15,823 Total lease liabilities $ 478,396 $ 513,251 A summary of the Company’s estimated operating lease payments are as follows: Year 2023 (1) $ 126,530 2024 162,991 2025 100,000 2026 100,000 2027 25,000 Thereafter - Total future lease payments 514,521 Less: Imputed interest 55,902 Present value of lease liability $ 458,619 (1) Excludes the three months ended March 31, 2023

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Purchase Commitments In October 2022, the Company entered into a non-cancelable purchase commitment with an international materials vendor for items needed for both development of the Symphony product line and also to resell to its customers. This agreement commits the Company to purchase approximately $800,000 in goods, of which 50% was prepaid in 2022. Approximately $90,000 of goods have been received under this arrangement as of March 31, 2023. The Company had multiple open purchase commitments with its primary contract manufacturing organization in Japan related to the buildout of a manufacturing line for the IL-6 cartridges for the Symphony device. As of March 31, 2023, the total open non-cancellable commitments for the manufacturing line buildout totaled approximately $127,000. As of March 31, 2023, the Company has entered into other non-cancelable purchase commitments primarily for research and development supplies, prototypes, and key advisory services. The purchase commitments covered by these agreements are for less than one year and aggregate to approximately $1.5 million. Minimum Royalties As required under the License Agreement (see Note 3), following the first sale of Cartridges, the Company will also make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or for 5 years after the first sale. Following the first sale, the Company will pay a one-time minimum royalty of $60,000, which shall be creditable against any royalties owed to Toray in such calendar year. The Company will pay a minimum royalty of $100,000 in each year thereafter, which are creditable against any royalties owed to Toray in such calendar year. There were no sales of or revenues from the Cartridges through March 31, 2023. Indemnification The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2023
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	10. SUPPLEMENTAL BALANCE SHEET INFORMATION Prepaid expenses and other current assets consist of the following: March 31, December 31, Prepaid insurance $ 564,361 $ 751,979 Vendor prepayments 1,195,193 681,218 Prepaid other 360,458 240,283 Total prepaid expenses and other current assets $ 2,120,012 $ 1,673,480 Accrued expenses and other current liabilities consist of the following: March 31, December 31, Accrued personnel costs $ 343,706 $ 533,577 Accrued good receipts 281,054 10,077 Accrued other 238,637 292,076 Total accrued expenses and other current liabilities $ 863,397 $ 835,730

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS On April 25, 2023, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until October 23, 2023. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten consecutive business days. The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock (if approved by the Company’s stockholders) to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Requirement during the 180-day additional compliance period or maintain compliance with the other Nasdaq listing requirements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.
Stock-based compensation	Stock-based compensation Share-based compensation expense for all share-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Share-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of share-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense.
Research and development expenses	Research and development expenses Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials. The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf.
Segment Reporting	Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of March 31, 2023 and December 31, 2022, all of the Company’s assets were located in the United States.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares): March 31, 2023 2022 Options to purchase common stock 739,835 806,065 Restricted stock units 197,500 - Warrants for common stock 811,882 811,882 Class A warrants for common stock 2,484,000 2,484,000 Class B warrants for common stock 75,400 76,500
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 805”) Revenue from Contracts with Customers (Topic 606) (“

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of diluted net loss per share	March 31, 2023 2022 Options to purchase common stock 739,835 806,065 Restricted stock units 197,500 - Warrants for common stock 811,882 811,882 Class A warrants for common stock 2,484,000 2,484,000 Class B warrants for common stock 75,400 76,500

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Warrants [Abstract]
Schedule of information with regard to warrants outstanding	Shares Exercisable for Weighted Average Exercise Price Weighted Average Remaining Life (in Years) Common Stock Warrants 811,882 Common Stock $ 3.24 2.8 Class A Warrants 2,484,000 Common Stock $ 7.00 3.6 Class B Warrants 75,400 Common Stock $ 10.00 1 3.6 1 Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below.

Stock Compensation (Tables)

Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Stock Compensation [Abstract]
Schedule of non-vested restricted stock awards	Non-vested Number of Weighted Outstanding at December 31, 2022 60,000 $ 1.29 Granted 512,180 0.44 Vested (374,680 ) 0.44 Forfeited - - Outstanding at March 31, 2023 197,500 $ 0.70
Schedule of stock option activity	Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 719,835 $ 1.96 6.5 $ 20,578 Granted 20,000 0.53 Exercised - - - - Cancelled and forfeited - - - - Outstanding at March 31, 2023 739,835 $ 1.92 7.7 $ 23,316 Exercisable at March 31, 2023 564,440 $ 1.86 7.4 $ 23,316
Schedule of grant-date fair value of share-based awards granted	Three Months Ended 2023 2022 Risk-free interest rate 3.63% 1.58% - 2.40% Expected dividend yield 0.00% 0.00% Volatility factor 108.78% 102.03% Expected life of option (in years) 6.00 5.37 – 6.00
Schedule of stock-based compensation expense	Three Months Ended 2023 2022 Research and development $ 44,845 $ 17,311 General and administrative 159,584 108,305 Sales and marketing 15,160 470 Total stock-based compensation $ 219,589 $ 126,086

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Schedule of summarizes the amounts incurred	Three Months Ended 2023 2022 Income from NanoHybrids included in Other Income $ 95,798 $ 40,886 Cash receipts from NanoHybrids $ 19,731 $ 22,539 As of March 31, December 31, Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets $ 95,798 $ 19,731

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Depreciable March 31, December 31, Construction-in-process $ 768,850 $ 375,466 Furniture, fixtures, and equipment 3-5 years 143,649 136,942 Software 3-5 years 4,457 4,457 Lab equipment 3-5 years 1,275,958 1,268,380 Leasehold improvements Shorter of useful life of life of lease 43,231 43,231 2,236,145 1,828,476 Less: accumulated depreciation (716,423 ) (596,406 ) Property and equipment, net $ 1,519,722 $ 1,232,070

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of lease arrangements for office and laboratory space	Three Months Ended March 31, March 31, Weighted average remaining lease term – operating leases (in years) 3.5 4.3 Weighted average remaining lease term – finance leases (in years) 4.8 - Weighted average discount rate 7.0 % 7.0 % Operating cash flows from operating leases $ 43,564 $ 29,248 Operating cash flows from finance leases $ 1,202 -
Schedule of lease assets and liabilities	March 31, December 31, Operating lease right-of-use asset $ 433,361 $ 465,514 Finance lease asset – property & equipment, net 21,067 21,067 Total lease assets 454,428 486,581 Current portion of operating lease liability included in accrued expenses 168,709 168,706 Current portion of finance lease liability included in accrued expenses 4,807 4,807 Non-current operating lease liabilities 289,910 323,915 Non-current finance lease liabilities included in other non-current liabilities 14,970 15,823 Total lease liabilities $ 478,396 $ 513,251
Schedule of estimated lease payments	Year 2023 (1) $ 126,530 2024 162,991 2025 100,000 2026 100,000 2027 25,000 Thereafter - Total future lease payments 514,521 Less: Imputed interest 55,902 Present value of lease liability $ 458,619 (1) Excludes the three months ended March 31, 2023

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Balance Sheet Information [Abstract]
Schedule of prepaid expenses and other current assets	March 31, December 31, Prepaid insurance $ 564,361 $ 751,979 Vendor prepayments 1,195,193 681,218 Prepaid other 360,458 240,283 Total prepaid expenses and other current assets $ 2,120,012 $ 1,673,480
Schedule of accrued expenses and other current liabilities	March 31, December 31, Accrued personnel costs $ 343,706 $ 533,577 Accrued good receipts 281,054 10,077 Accrued other 238,637 292,076 Total accrued expenses and other current liabilities $ 863,397 $ 835,730

Nature of Operations and Basi_2

Nature of Operations and Basis of Presentation (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares
Accounting Policies [Abstract]
Common stock per share (in Dollars per share) | $ / shares	$ 1
Cash and cash equivalents.	$ 6.8
Accounts payable and accrued expenses	1.4
Capital commitments	$ 2.5

Significant Accounting Polici_3

Significant Accounting Policies (Details) - Schedule of diluted net loss per share - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule Of Diluted Net Loss Per Share [Abstract]
Options to purchase common stock	$ 739,835	$ 806,065
Restricted stock units	197,500
Warrants for common stock	811,882	811,882
Class A warrants for common stock	2,484,000	2,484,000
Class B warrants for common stock	$ 75,400	$ 76,500

License and Supply Agreement _2

License and Supply Agreement with Toray Industries (Details) - USD ($)		3 Months Ended
	Oct. 06, 2020	Mar. 31, 2023
License and Supply Agreement with Toray Industries (Details) [Line Items]
Percentage of royalty payments	15%
Sale term	5 years
Maximum [Member]
License and Supply Agreement with Toray Industries (Details) [Line Items]
Annual royalty payments		$ 100,000
Minimum [Member]
License and Supply Agreement with Toray Industries (Details) [Line Items]
Annual royalty payments		$ 60,000

Warrants (Details)

Warrants (Details) - USD ($)	1 Months Ended	3 Months Ended
	Nov. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Warrants (Details) [Line Items]
Class B Warrant rights, description		Holders of Class B Warrants may also exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement).
Class A Warrants [Member]
Warrants (Details) [Line Items]
Initial public offering proceeds (in Dollars)	$ 5,164,751
Class B Warrants [Member]
Warrants (Details) [Line Items]
Initial public offering proceeds (in Dollars)	$ 7,323,161
Warrants exercised		39,000
Class A Warrants [Member]
Warrants (Details) [Line Items]
Warrants issued	2,160,000
Additional issuance of warrants	324,000
Issuance exercise price, per share (in Dollars per share)		$ 7	$ 7
Class B Warrants [Member]
Warrants (Details) [Line Items]
Warrants issued	2,160,000
Additional issuance of warrants	324,000
Issuance exercise price, per share (in Dollars per share)		$ 10
Warrants outstanding		75,400	76,500

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of information with regard to warrants outstanding	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Common Stock Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Abstract]
Shares | shares	811,882
Exercisable for	Common Stock
Weighted Average Exercise Price | $ / shares	$ 3.24
Weighted Average Remaining Life (in Years)	2 years 9 months 18 days
Class A Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Abstract]
Shares | shares	2,484,000
Exercisable for	Common Stock
Weighted Average Exercise Price | $ / shares	$ 7
Weighted Average Remaining Life (in Years)	3 years 7 months 6 days
Class B Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Abstract]
Shares | shares	75,400
Exercisable for	Common Stock
Weighted Average Exercise Price | $ / shares	$ 10	[1]
Weighted Average Remaining Life (in Years)	3 years 7 months 6 days
[1] Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below.

Stock Compensation (Details)

Stock Compensation (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Feb. 23, 2023
Stock Compensation (Details) [Line Items]
RSU bonus grant			374,680
Weighted average grant date fair value of options granted (in Dollars per share)	$ 0.44	$ 1.48
Unrecognized compensation expense (in Dollars)	$ 89,451
Weighted-average period	1 year 1 month 6 days
Non-vested stock option [Member]
Stock Compensation (Details) [Line Items]
Unrecognized compensation expense (in Dollars)	$ 114,985
Weighted-average period	1 year 9 months 18 days
2018 Stock Incentive Plan [Member]
Stock Compensation (Details) [Line Items]
Shares reserved for issuance	629,440
Shares available for grants	262,269
2021 Plan [Member]
Stock Compensation (Details) [Line Items]
Shares reserved for issuance	1,960,000
Shares available for grants	807,541

Stock Compensation (Details) -

Stock Compensation (Details) - Schedule of non-vested restricted stock awards	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Schedule of Non Vested Restricted Stock Awards [Abstract]
Number of Shares, Outstanding at beginning balance | shares	60,000
Weighted Average Grant Date Fair Value, Outstanding at beginning balance | $ / shares	$ 1.29
Number of Shares, Granted | shares	512,180
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 0.44
Number of Shares, Vested | shares	(374,680)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 0.44
Number of Shares, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Shares, Outstanding at ending balance | shares	197,500
Weighted Average Grant Date Fair Value, Outstanding at ending balance | $ / shares	$ 700,000

Stock Compensation (Details) _2

Stock Compensation (Details) - Schedule of stock option activity	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Schedule of Stock Option Activity [Abstract]
Number of Stock Options, Outstanding at beginning balance | shares	719,835
Weighted Average Exercise Price Per Share, Outstanding at beginning balance | $ / shares	$ 1.96
Weighted Average Remaining Contractual Life in Years, Outstanding at beginning balance	6 years 6 months
Aggregate Intrinsic Value, Outstanding at beginning balance | $	$ 20,578
Number of Stock Options, Outstanding at ending balance | shares	739,835
Weighted Average Exercise Price Per Share, Outstanding at ending balance | $ / shares	$ 1.92
Weighted Average Remaining Contractual Life in Years, Outstanding at ending balance	7 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding at ending balance | $	$ 23,316
Number of Stock Options, Exercisable | shares	564,440
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 1.86
Weighted Average Remaining Contractual Life in Years, Exercisable	7 years 4 months 24 days
Aggregate Intrinsic Value,Exercisable | $	$ 23,316
Number of Stock Options, Granted | shares	20,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 0.53
Number of Stock Options, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Weighted Average Remaining Contractual Life in Years, Exercised
Aggregate Intrinsic Value, Exercised | $
Number of Stock Options, Cancelled and forfeited | shares
Weighted Average Exercise Price Per Share, Cancelled and forfeited | $ / shares
Weighted Average Remaining Contractual Life in Years, Cancelled and forfeited
Aggregate Intrinsic Value, Cancelled and forfeited | $

Stock Compensation (Details) _3

Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Minimum [Member]
Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted [Line Items]
Risk-free interest rate	3.63%	1.58%
Expected dividend yield	0%
Volatility factor	108.78%
Expected life of option (in years)	6 years	5 years 4 months 13 days
Maximum [Member]
Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted [Line Items]
Risk-free interest rate		2.40%
Expected dividend yield		0%
Volatility factor		102.03%
Expected life of option (in years)		6 years

Stock Compensation (Details) _4

Stock Compensation (Details) - Schedule of stock-based compensation expense - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 219,589	$ 126,086
Research and development [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	44,845	17,311
General and administrative [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	159,584	108,305
Sales and Marketing [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 15,160	$ 470

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Percentage of employees cost	10%

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of amounts earned and due - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule Of Amounts Earned And Due [Abstract]
Income from NanoHybrids included in Other Income	$ 95,798	$ 40,886
Cash receipts from NanoHybrids	19,731	22,539
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets	$ 95,798	$ 19,731

Property and Equipment (Details

Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Property, Plant and Equipment [Abstract]
Additional depreciation	$ 45,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 2,236,145	$ 1,828,476
Less: accumulated depreciation	(716,423)	(596,406)
Property and equipment, net	1,519,722	1,232,070
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	768,850	375,466
Furniture, fixtures, and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 143,649	136,942
Furniture, fixtures, and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Furniture, fixtures, and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 4,457	4,457
Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 1,275,958	1,268,380
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	Shorter of useful life of life of lease
Property and equipment, total	$ 43,231	$ 43,231

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease arrangements for office and laboratory space - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule of lease arrangements for office and laboratory space [Abstract]
Weighted average remaining lease term – operating leases (in years)	3 years 6 months	4 years 3 months 18 days
Weighted average remaining lease term – finance leases (in years)	4 years 9 months 18 days
Weighted average discount rate	7%	7%
Operating cash flows from operating leases	$ 43,564	$ 29,248
Operating cash flows from finance leases	$ 1,202

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of lease assets and liabilities - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Schedule of lease assets and liabilities [Abstract]
Operating lease right-of-use asset	$ 433,361	$ 465,514
Finance lease asset – property & equipment, net	21,067	21,067
Total lease assets	454,428	486,581
Current portion of operating lease liability included in accrued expenses	168,709	168,706
Current portion of finance lease liability included in accrued expenses	4,807	4,807
Non-current operating lease liabilities	289,910	323,915
Non-current finance lease liabilities included in other non-current liabilities	14,970	15,823
Total lease liabilities	$ 478,396	$ 513,251

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of estimated lease payments	Mar. 31, 2023 USD ($)
Schedule of estimated lease payments [Abstract]
2023	$ 126,530	[1]
2024	162,991
2025	100,000
2026	100,000
2027	25,000
Thereafter
Total future lease payments	514,521
Less: Imputed interest	55,902
Present value of lease liability	$ 458,619
[1] Excludes the three months ended March 31, 2023

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase of goods	$ 800,000
Prepaid percentage	50%
Portion expensed	$ 90,000
Total approximately	127,000
Aggregate amount	$ 1,500,000
Toray royalty commitment	As required under the License Agreement (see Note 3), following the first sale of Cartridges, the Company will also make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or for 5 years after the first sale. Following the first sale, the Company will pay a one-time minimum royalty of $60,000, which shall be creditable against any royalties owed to Toray in such calendar year. The Company will pay a minimum royalty of $100,000 in each year thereafter, which are creditable against any royalties owed to Toray in such calendar year.

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information (Details) - Schedule of prepaid expenses and other current assets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 564,361	$ 751,979
Vendor prepayments	1,195,193	681,218
Prepaid other	360,458	240,283
Total prepaid expenses and other current assets	$ 2,120,012	$ 1,673,480

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]
Accrued personnel costs	$ 343,706	$ 533,577
Accrued good receipts	281,054	10,077
Accrued other	238,637	292,076
Total accrued expenses and other current liabilities	$ 863,397	$ 835,730

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Apr. 25, 2023 $ / shares
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Bid price	$ 1